Skip to main content
. Author manuscript; available in PMC: 2013 Jul 2.
Published in final edited form as: Br J Haematol. 2011 Oct 20;155(4):457–467. doi: 10.1111/j.1365-2141.2011.08882.x

Table II.

Modulation of surface expression of costimulatory molecules on CLL cells after in vivo lenalidomide treatment.

27
30
25
Patient Day 0 Day 7 Day 0 Day 7 Day 0 Day 7
CD95 33 34 70 77 5 5
CD83 4 10 6 17 6 5
CD40 14 25 4 18 9 8
CD80 1 1 4 15 31 22
CD86 15 22 2 10 8 7
CD59 83 96 92 96 97 95
DR 83 82 34 76 99 99

Peripheral blood was collected from patients enrolled on the clinical trial at baseline and then at day 7 of treatment with single agent lenalidomide. Surface expression of costimulatory molecules was assessed by flow cytometry gated on CD19+ B cells.

The bold values represent antigen expression pattern with significant changes induced by lenalidomide treatment in vitro.